Roivant Sciences (NASDAQ:ROIV) Director Sells 602,021 Shares of Stock

Roivant Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Roivant Sciences director Daniel Gold sold 602,021 shares on November 17 at an average price of $38.24, worth about $23.0 million. The previous day, he sold another 779,741 shares for approximately $30.5 million.
  • ROIV shares traded at $38.73, within a 12-month range of $19.96 to $42.50; institutional investors hold 64.76% of the stock.
  • Analyst sentiment is generally positive: the stock has a “Moderate Buy” consensus rating and an average price target of $46.82.
  • Interested in Roivant Sciences? Here are five stocks we like better.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Gold sold 602,021 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $38.24, for a total value of $23,021,283.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

  • On Monday, November 16th, Daniel Gold sold 779,741 shares of Roivant Sciences stock. The stock was sold at an average price of $39.14, for a total value of $30,519,062.74.

Roivant Sciences Price Performance

Shares of ROIV traded up $0.02 during trading hours on Wednesday, hitting $38.73. The stock had a trading volume of 3,724,435 shares, compared to its average volume of 6,586,585. Roivant Sciences Ltd. has a 12 month low of $19.96 and a 12 month high of $42.50. The firm has a market capitalization of $28.06 billion, a PE ratio of -61.48 and a beta of 1.23. The stock has a fifty day moving average price of $37.32 and a 200 day moving average price of $32.42.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. Assenagon Asset Management S.A. lifted its position in Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock valued at $295,965,000 after purchasing an additional 1,286,464 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Roivant Sciences by 3.8% during the first quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company's stock valued at $229,507,000 after purchasing an additional 300,000 shares during the period. Pictet Asset Management Holding SA increased its position in Roivant Sciences by 20.3% in the third quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company's stock worth $152,597,000 after buying an additional 704,783 shares in the last quarter. Bank of America Corp DE increased its position in Roivant Sciences by 8.0% in the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company's stock worth $87,638,000 after buying an additional 235,493 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Roivant Sciences by 6.1% in the first quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company's stock worth $85,790,000 after buying an additional 177,339 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ROIV has been the topic of several research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 24th. HC Wainwright upped their price target on shares of Roivant Sciences from $47.00 to $48.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. Jefferies Financial Group increased their price objective on shares of Roivant Sciences from $42.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. Wolfe Research downgraded shares of Roivant Sciences from an "outperform" rating to a "peer perform" rating in a report on Monday, October 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Roivant Sciences in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.82.

View Our Latest Research Report on ROIV

About Roivant Sciences

(Get Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Recommended Stories

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Roivant Sciences Right Now?

Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines